Floatz logo

mk-6240

Spinal Radiculopathy

Yale UniversityPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Spinal Radiculopathy cohort.

Asset / SponsorPhaseRating
Triamcinalone
University of Miami
Phase 4BBB
LIDOCAINE
Sheba Medical Center
Phase 4BBB
sp-102
Semnur Pharmaceuticals, Inc.
Phase 3BB
DEXAMETHASONE
Semnur Pharmaceuticals, Inc.
Phase 4BB
Celestone
Sheba Medical Center
Phase 4BB

View all 37 →

Same molecule, other indications

mk-6240 is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
65 / 100
View asset →
Down syndromeDormant
B
Indicative ·
60 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →